Active Shortage Injection Oncology

Carboplatin Injection · 1,232 days since initial FDA posting

Brand: CARBOPLATIN

FDA lists Carboplatin Injection as Active Shortage (Teyro Labs).

Availability on file: Unavailable

Carboplatin Injection: Active Shortage

Unavailable Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Carboplatin Injection
Manufacturer
Teyro Labs
Dosage Form
Injection
Presentation
Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)
Package NDC
60505-6282-7

Status & Timeline

Status
Active Shortage
Availability
Unavailable
First Reported
Apr 28, 2023
Last Updated
Mar 17, 2026
Therapeutic Category
Oncology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Replenishment Late March 2026; Discontinuation of the manufacture of the drug.

Nearby, Other Carboplatin Shortage Records

Carboplatin Injection

Gland Pharma Limited

Injection

Active Shortage

Carboplatin Injection

Gland Pharma Limited

Injection

Active Shortage

Carboplatin Injection

Gland Pharma Limited

Injection

Active Shortage

Carboplatin Injection

Gland Pharma Limited

Injection

Active Shortage

Carboplatin Injection

Teyro Labs

Injection

Active Shortage

Carboplatin Injection

Teyro Labs

Injection

Active Shortage

FDA reason on file: Replenishment Late March 2026; Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages